Critical Path Institute (C-Path) has named Daniel M. Jorgensen, M.D., MPH, MBA, as its Chief Executive Officer as of October 1^st. Jorgensen is an experienced leader in drug development, healthcare and business, and will continue C-Path’s collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. 
 
“Dr. Jorgensen has long been a visionary in drug development, applying his vast insight, experience and passion for healthcare to advancing every organization he has been a part of,” said Kristen Swingle, M.S., C-Path’s COO and President. “We’re excited to welcome him to C-Path and to be able to benefit from his leadership and expertise.”
 

Jorgensen is an accomplished physician executive with more than 24 years of experience in the biopharmaceutical industry, in both small and large companies, public and private, including C-level positions for the past 11 years. Before C-Path, he was CEO at AxoProtego, guiding the neuroscience startup through funding and partnership activities.
 
Jorgensen began his career as a pediatrician and worked at the Centers for Disease Control & Prevention (CDC) and other public health organizations before taking his first job in the industry, developing vaccines for Pasteur Merieux Connaught. Jorgensen also spent 10 years at Pfizer, as the Global Clinical Leader for azithromycin and was named Pfizer’s first Vaccine Development Team Leader, playing a key role in multiple FDA meetings, submissions and approvals. He also served as Chief Medical Officer at several biotechnology companies, developing drugs across multiple therapeutic areas.
 
“Dan’s deep pharmaceutical and regulatory expertise makes him the perfect choice to drive C-Path into the future,” said Wainwright Fishburn, C-Path Board Chair. “We were searching for a bold leader with an outstanding background to execute our strategic roadmap for continued organizational growth globally, and we’re thrilled that he’ll be leading the organization.”

“C-Path has an excellent reputation in advancing medical innovation and global health in a way that is uniquely collaborative, and I am thrilled to be part of its mission,” Jorgensen said. “We have a lot of exciting goals for the years ahead and I’m looking forward to hitting the ground running, with the support of C-Path’s outstanding staff and extended stakeholders.”